Agenus Inc. (NASDAQ:AGEN) Given Average Recommendation of “Hold” by Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have been given an average rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Thursday, December 5th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its position in shares of Agenus by 295.3% during the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 20,777 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Agenus by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after purchasing an additional 32,016 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Agenus during the third quarter valued at about $55,000. State Street Corp increased its holdings in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares during the last quarter. Finally, Point72 DIFC Ltd lifted its position in shares of Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after buying an additional 11,542 shares in the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Price Performance

Shares of AGEN stock opened at $2.83 on Monday. Agenus has a 1 year low of $2.50 and a 1 year high of $19.69. The firm has a fifty day moving average price of $3.64 and a 200-day moving average price of $6.99. The company has a market cap of $66.39 million, a price-to-earnings ratio of -0.25 and a beta of 1.25.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.